Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2005

View Archived Issues

RWJ-351647 benefits patients with cirrhotic ascites

Mitemcinal dose-dependently reduces diabetic gastroparesis

Prokinetic Z-338 tested in patients with functional dyspepsia

Linomide analogue Lin-05 demonstrates potent antiangiogenic activity

Effects of AZD-0865 on gastric acid secretion investigated in humans and dogs

Fluoglizine produces antidepressive effects in vivo

Anxiolytic and anticonvulsant properties described for 1-(phenylpiperazinylbutyl) acids

Bevacizumab plus chemotherapy improves survival in cancer patients

No statistically significant effects of PTK/ZK in metastatic colorectal cancer

Access to sorafenib for U.S. advanced kidney cancer patients

Lubiprostone enters phase III for constipation-predominant IBS

BioMarin and Serono sign agreement for Phenoptin and Phenylase

Spectrum acquires licenses to lucanthone

U.K. study begins for StaphVAX in orthopedic patients

MD-1100 successfully completes phase Ia study

NovImmune grants Serono rights to NI-0401 and NI-0501

Organon and Lexicon Genetics to develop biotherapeutic drugs

Corautus and BI enter manufacturing agreement for VEGF2 plasmid DNA

Update on the anticancer effects of AP-23573

Alcon presents data on novel VEGFR inhibitors for CNV

Tag-It Cystic Fibrosis Kit receives FDA approval

Recent patents describe new antiinfective agents

New therapeutic agents for respiratory diseases reported in recent patent literature

Sumitomo licenses SMP-601 to Protez

Pegasys approved for chronic hepatitis B

Novel cathepsin K inhibitors discovered at GlaxoSmithKline

Antidiabetic drugs revealed in patents

Bispecific T-cell engager MT-103 causes serial killing of target tumor cells

RSV fusion inhibitor with potential for oral administration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...